A Phase 1 interventional study of tucatinib in Healthy, sponsored by Cascadian Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-29.
Sponsored by Cascadian Therapeutics Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib while it is still in the body. Healthy participants will get one dose of tucatinib by mouth. Patients will be monitored for 8-14 days after they take the dose of tucatinib.
This study will examine the absorption, metabolism, and excretion of tucatinib in healthy individuals. Participants will receive one oral dose of tucatinib and will be followed for 8-14 days after the dose is received.
Cascadian Therapeutics Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
First submitted before Cascadian Therapeutics Inc. became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tucatinib
Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity
Area under the concentration-time curve (AUC) from time 0 to infinity (AUC[0-inf])
PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles
Time frame: Up to 14 days
AUC from time 0 to last quantifiable concentration
PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles
Time frame: Up to 14 days
Maximum observed concentration
PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles
Time frame: Up to 14 days
Time of maximum observed concentration
PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles
Time frame: Up to 14 days
Apparent terminal elimination half-life
PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles
Time frame: Up to 14 days
Apparent total clearance
PK outcome parameter for tucatinib derived from the whole blood and plasma concentration-time profiles
Time frame: Up to 14 days
Apparent volume of distribution
PK outcome parameter for tucatinib derived from the whole blood and plasma concentration-time profiles
Time frame: Up to 14 days
AUC[0-inf] plasma tucatinib/total radioactivity ratio
AUC\[0-inf\] of plasma tucatinib relative to AUC\[0-inf\] of plasma total radioactivity
Time frame: Up to 14 days
AUC[0-inf] blood/plasma ratio
AUC\[0-inf\] of whole blood total radioactivity to AUC\[0-inf\] of plasma total radioactivity
Time frame: Up to 14 days
Amount excreted in urine (Aeu)
PK outcome endpoint of tucatinib, ONT-993, and total radioactivity derived from urine collections
Time frame: Up to 14 days
Cumulative Aeu
PK outcome endpoint of tucatinib, ONT-993, and total radioactivity derived from urine collections
Time frame: Up to 14 days
Percentage excreted in urine (Feu)
PK outcome endpoint of tucatinib and total radioactivity derived from urine collections
Time frame: Up to 14 days
Cumulative Feu
PK outcome endpoint of tucatinib and total radioactivity derived from urine collections
Time frame: Up 14 days
Renal clearance
PK outcome endpoint of tucatinib derived from urine collections
Time frame: Up to 14 days
Amount excreted in feces [Aef]
PK outcome endpoint of total radioactivity derived from feces collection
Time frame: Up to 14 days
Cumulative Aef
PK outcome endpoint of total radioactivity derived from feces collection
Time frame: Up to 14 days
Percentage excreted in feces [Fef]
PK outcome endpoint of total radioactivity derived from feces collection
Time frame: Up to 14 days
Cumulative Fef
PK outcome endpoint of total radioactivity derived from feces collection
Time frame: Up to 14 days
Relative abundance of tucatinib and its metabolites eliminated in urine and feces
Time frame: Up to 14 days
Relative abundance of tucatinib and its metabolites in plasma
Time frame: Up to 14 days
Incidence of adverse events (AEs)
Time frame: Up to 14 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2017 to primary completion in Jan 2018, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tucatinib